382
Participants
Start Date
April 30, 2011
Primary Completion Date
July 31, 2013
Study Completion Date
October 31, 2013
A-623
High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
A-623
Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
A-623
High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
Investigator Site 351, Taiwan
Investigator Site 354, Taichung
Investigator Site 352, Dawan
Investigator Site 304, Manila
Investigator Site 408, San Juan
Investigator Site 302, Cebu City
Investigator Site 807, México
Investigator Site 303, Davao City
Investigator Site 305, Davao City
Investigator Site 106, Lake Success
Investigator Site 114, Smithtown
Investigator Site 809, Mexico City
Investigator Site 117, Baltimore
Investigator Site 101, Greenville
Investigator Site 105, Orlando
Investigator Site 102, Tampa
Investigator Site 103, Birmingham
Investigator Site 808, León
Investigator Site 806, Guadalajara
Investigator Site 104, Lansing
Investigator Site 802, Toluca
Investigator Site 804, Morelia
Investigator Site 112, Oklahoma City
Investigator Site 111, Tulsa
Investigator Site 115, Houston
Investigator Site 801, San Luis Potosí City
Investigator Site 113, Long Beach
Investigator Site 110, Upland
Investigator Site 201, Mumbai
Investigator Site 203, Bangalore
Investigator Site 204, Trivandrum
Investigator Site 601, Viña del Mar
Investigator Site 606, Santiago
Investigator Site 602, Santiago
Investigator Site 507, Goiânia
Investigator Site 404, Caba
Investigator Site 402, Caba
Investigator Site 407, Caba
Investigator Site 401, Caba
Investigator Site 403, Rosario
Investigator Site 406, San Miguel de Tucumán
Investigator Site 504, Salvador
Investigator Site 509, Goiás
Investigator Site 506, Juiz de Fora
Investigator Site 511, Rio de Janeiro
Investigator Site 503, Rio de Janeiro
Investigator Site 502, Porto Alegre
Investigator 505, São Paulo
Investigator Site 501, São Paulo
Investigator Site 510, São Paulo
Investigator Site 605, Santiago
Investigator Site 706, Medellín
Investigator Site 708, Medellín
Investigator Site 710, Medellín
Investigator Site 701, Barranquilla
Investigator Site 704, Barranquilla
Investigator Site 702, Bogota
Investigator Site 709, Bogota
Investigator Site 707, Bucaramanga
Investigator Site 711, Bucaramanga
Investigator Site 153, New Territories
Investigator Site 151, Hong Kong
Investigator Site 905, Lima
Investigator Site 901, Arequipa
Investigator Site 902, Callao
Investigator Site 705, Bogota
Investigator Site 205, Hyderabad
Investigator Site 805, México
Investigator Site 803, Mexico City
Investigator Site 903, Lima
Investigator Site 904, Lima
Lead Sponsor
Anthera Pharmaceuticals
INDUSTRY